Design Therapeutics (DSGN) Research & Development (2020 - 2026)

Design Therapeutics has disclosed Research & Development across 7 years of filings, most recently posting $14.4 million for Q1 2026.

• Research & Development for Q1 2026 came in at $14.4 million, down 6.49% year-over-year; the trailing twelve-month figure through Mar 2026 was -$898000.0 (down 101.8% YoY), and the FY2025 annual result was $100000.0, down 99.77% from the prior year.
• Research & Development came in at $14.4 million for Q1 2026 at Design Therapeutics, up from -$45.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $17.1 million in Q2 2023 to a low of -$45.6 million in Q4 2025.
• The 5-year median for Research & Development is $13.3 million (2023), against an average of $9.7 million.
• Across the five-year window, Research & Development jumped 126.04% in 2022 and sank 475.13% in 2025, its largest moves.
• Design Therapeutics' Research & Development stood at $14.3 million in 2022, then declined by 22.75% to $11.0 million in 2023, then rose by 10.4% to $12.2 million in 2024, then tumbled by 475.13% to -$45.6 million in 2025, then jumped by 131.53% to $14.4 million in 2026.
• The last three Research & Development figures came in at $14.4 million (Q1 2026), -$45.6 million (Q4 2025), and $14.6 million (Q3 2025), per Business Quant data.